Osteogenesis Imperfecta — Research Summary
Printed from RareWays (rareways.com.au) on 11 June 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Adipose-derived mesenchymal stem cells-derived exosomes containing nano-pearl powder water-soluble matrix promote osteogenic differentiation of MC3T3-E1 cells.
Chen Ling et al. — Organogenesis (31 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41746760/
- 2.
Integrated targeted metabolomics and transcriptomics analysis reveals heterogeneity of subcutaneous and pericardial adipose tissues in Yili horses.
Yang Liping et al. — Food chemistry. Molecular sciences (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41660677/
- 3.
Sinominine alleviates pulmonary fibrosis by suppressing macrophage-to-myofibroblast transition via inhibition of the Frem1/NF-κB/IL-1β axis.
Zheng Junhui et al. — International immunopharmacology (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41833105/
- 4.
Salvianolic acid C attenuates liver fibrosis and inhibites hepatic stellate cell activation by targeting FAP/TβRI/SMAD axis.
Sun Tao et al. — International immunopharmacology (15 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41740338/
- 5.
Polystyrene nanoplastics exacerbate dibutyl phthalate-induced liver fibrosis through PDGFRα-dependent hepatic stellate cell activation.
Baek Eun Bok et al. — Environmental pollution (Barking, Essex : 1987) (15 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41638286/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Recruiting — Phase 3 — Amgen
https://clinicaltrials.gov/study/NCT07213674
- 2.
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
Recruiting — Phase 3 — Amgen
https://clinicaltrials.gov/study/NCT05972551
- 3.
Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)
Recruiting — Phase 2 — Angitia Incorporated Limited
https://clinicaltrials.gov/study/NCT07062588
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Osteogenesis Imperfecta
Osteogenesis imperfecta (brittle bone disease) is a group of genetic conditions causing fragile bones that fracture easily. Most cases are caused by mutations in collagen genes. Severity ranges from mild to severe. Bisphosphonate therapy strengthens bones, and new treatments including gene-based approaches are in trials.
Most Recent Research
OBJECTIVE: To explore the synergistic effect of nano-pearl powder (NPP) and adipose-derived stem cell exosomes (ADSC-Exos) on the osteogenic potential of MC3T3-E1 cells. METHODS: The water-soluble matrix of NPP (NPP-WSM) was extracted via freeze-drying, and ADSC-Exos were isolated by ultracentrifugation. NPP-WSM was incorporated into ADSC-Exos through co-incubation to generate NPP-WSM-Exos. MC3T3-E1 cells were treated with NPP-WSM or NPP-WSM-Exos. Cell proliferation and migration were evaluated using CCK-8 and wound-healing assays, respectively. Osteogenic differentiation was assessed by Alizarin Red S staining and alkaline phosphatase (ALP) activity. The expression of osteogenesis-related genes (COL1A1, RUNX2, OCN, and OPN) was measured by qPCR and Western blotting. Transcriptome sequencing (RNA-seq) was conducted to identify signaling pathways activated by NPP-WSM-Exos. RESULTS: NPP-WSM-Exos displayed distinct exosome morphology and biomarkers, confirming their successful preparation. Significantly, NPP-WSM-Exos enhanced the viability of MC3T3-E1 cells compared to NPP-WSM alone and upregulated the expression of osteogenic genes, including COL1A1, RUNX2, OCN, and OPN, at both the transcriptional and translational levels. Additionally, NPP-WSM-Exos strongly promoted mineralization, as evidenced by the increased calcification observed through Alizarin Red S staining, and elevated alkaline phosphatase (ALP) activity, indicating excellent potential for osteogenic differentiation. Transcriptome sequencing showed that NPP-WSM-Exos significantly enhanced the PI3K/AKT pathway in MC3T3-E1 cells, while protein level detection indicated that NPP-WSM-Exos could increase AKT phosphorylation levels and inhibit GSK3β activity to improve osteogenic efficiency. CONCLUSION: The use of adipose-derived stem cell exosomes to encapsulate NPP-WSM can increase the utilization of WSM, promote the proliferation of MC3T3-E1, and enhance the osteogenic differentiation ability.
Common Questions
What is Osteogenesis Imperfecta?
Osteogenesis imperfecta (brittle bone disease) is a group of genetic conditions causing fragile bones that fracture easily. Most cases are caused by mutations in collagen genes. Severity ranges from mild to severe. Bisphosphonate therapy strengthens bones, and new treatments including gene-based approaches are in trials.
How many clinical trials are available for Osteogenesis Imperfecta?
RareWays currently indexes 95 clinical trials for Osteogenesis Imperfecta, of which 18 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Osteogenesis Imperfecta come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Osteogenesis Imperfecta.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.